Renowned A.I. expert, Prof. Mikael Boesen, MD, PhD, addressed the OARSI community and drug development companies in a recent webinar on the Role of Artificial Intelligence in Imaging.

The webinar, titled “Role of Artificial Intelligence in Imaging: Implications for Drug Development,” took place on Wednesday, May 15, 2024, from 8:00 to 9:00 am ET. This event served as a platform for scientists and industry leaders to explore the transformative potential of AI in medical imaging within the context of drug development.

Prof. Boesen, currently Professor of MSK Radiology & AI and Co-Founder of RAIT.dk and CLIC-project.org, offered strategic perspectives and actionable insights to empower drug development experts in navigating the evolving landscape of AI in medical imaging1.

The webinar covered key topics including:

• The role of AI in streamlining imaging processes in drug development

• Leveraging AI-powered image analysis for enhanced efficacy and safety assessments in clinical trials

• Strategies for integrating AI technologies into existing workflows

• Regulatory considerations and best practices for deploying AI solutions in drug development settings

For those who missed the live event, the recorded webinar is now available for viewing. Chief Medical Officers, medical directors, and other senior executives involved in drug development and clinical research can access the recording and follow up with Prof. Boesen by emailing their questions to imaging.experts@ia-grp.com.

To register and view the recorded webinar, please visit: https://oarsi.org/education/oarsi-live-webinar-series

This webinar was organized by Image Analysis Group (IAG), a leading imaging Clinical Research Organization that combines medical and operational expertise with cutting-edge proprietary A.I. capabilities to power drug development. IAG has been serving biotech and pharma clients globally since 2007, supporting all aspects of phase I to III imaging trials across multiple indications.

AI and Precision Medicine in Solid Tumors

AI and Precision Medicine in Solid Tumors

The webinar “AI and Precision Medicine in Solid Tumors” has already taken place. However, for those interested in the valuable insights shared during this event, the recorded discussion is now available.

Key topics covered in the webinar included:

• Imaging endpoints in oncology and regulatory requirements

• Site vs central reading: benefits, challenges, and opportunities

• Assessment criteria in solid tumors: choosing the right criteria

• Volumetrics and radiomics in solid tumors

The expert presenters were:

• Dr. Anitha Singareddy: A board-certified physician with over 13 years of experience in clinical research, CRO industry, and medical imaging, particularly in solid tumor portfolio using RECIST 1.1, iRECIST, and other oncology review criteria.

• Dr. Andrew Patterson: An experienced researcher with over 70 papers focusing on the development of novel imaging biomarkers and expertise in selecting optimal imaging and AI strategies to accelerate drug development.

The discussion was moderated by Julia O’Lynn, who has 20+ years of expertise in targeted drug development and advanced radiologic imaging.

For those who missed the live event, you can access the recorded webinar by contacting Image Analysis Group (IAG) directly. IAG is a leading partner to life sciences companies, specializing in AI-powered drug development and precision medicine. They leverage their proprietary cloud-based platform, Dynamika™, to de-risk clinical development and accelerate the delivery of lifesaving therapies.

To request access to the webinar recording or for more information about IAG’s services in AI-powered drug development and precision medicine, please contact IAG directly through their website or official channels.

Join us to discuss rapidly progressive osteoarthritis (RPOA) and challenges of designing and executing Osteoarthritis clinical trials.

Link to the content

The webinar “Rapidly Progressive Osteoarthritis (RPOA) and Challenges of Designing and Executing Osteoarthritis Clinical Trials” has already taken place. However, for those interested in the valuable insights shared during this event, a recording may be available upon request.

This webinar focused on the challenges of designing osteoarthritis (OA) clinical trials, with a particular emphasis on accounting for patients who may develop rapidly progressive osteoarthritis (RPOA). Key discussion points included:

• Regulatory perspective and future directions in knee OA drug development

• Observational radiographic features that may lead to prompt diagnosis of RPOA

• Design of clinical trials of osteoarthritis and use of imaging in identifying RPOA

The expert panel featured:

1. Prof. Mikael Boesen: Professor of musculoskeletal imaging with 20 years of international experience in clinical research on inflammatory and degenerative joint diseases.

2. Dr. Lee Simon: Rheumatologist, physician, and research scientist with extensive drug development experience, including service as a director of an FDA division.

3. Dr. Olga Kubassova (Moderator): CEO of IAG, Image Analysis Group, with expertise in quantitative imaging and development of novel efficacy methodologies using AI and Machine Learning.

The webinar highlighted the importance of understanding RPOA and incorporating appropriate imaging strategies in clinical trial design to exclude at-risk patients and monitor patient safety. This approach is crucial for ensuring accurate trial outcomes and patient safety in osteoarthritis drug development.

For those interested in accessing the webinar recording or learning more about IAG’s services in AI-powered drug development and precision medicine for osteoarthritis, please contact Image Analysis Group (IAG) directly through their official channels.

Image Analysis Group, demonstrates thought leadership in precision medicine for neuro-oncology through their innovative approaches to clinical trials and drug development. Their expertise focuses on leveraging advanced imaging techniques, artificial intelligence (AI), and data analytics to enhance the diagnosis, treatment, and monitoring of brain tumors.

Key aspects of IAG’s thought leadership in precision medicine for neuro-oncology include:

1. Advanced Imaging Techniques: IAG emphasizes the importance of optimal imaging modalities and analysis methods to accurately assess tumor structure, function, and treatment response1. They recommend combining conventional anatomical MRI with more advanced techniques to capture subtle treatment-induced changes.

2. AI-Driven Analysis: IAG utilizes AI and machine learning algorithms to extract detailed information from medical images, enabling more precise tumor characterization, treatment planning, and response assessment. Their proprietary Dynamika™ platform integrates these AI capabilities for imaging data management and analysis.

3. Personalized Treatment Approaches: By leveraging AI and advanced imaging, IAG aims to address tumor heterogeneity and develop individualized treatment strategies for brain cancer patients.

4. Clinical Trial Optimization: IAG’s expertise helps in designing more effective clinical trials by selecting appropriate imaging endpoints, training sites, and implementing rigorous data collection and review processes.

5. Multidisciplinary Integration: IAG emphasizes the importance of combining insights from radiology, pathology, and genomics to provide a comprehensive approach to brain tumor management.

6. Automated Volumetric Assessment: IAG recognizes the potential of AI-based volumetric tumor assessments to provide more accurate and quantitative measures of treatment response compared to traditional methods like RANO criteria.

By focusing on these areas, IAG positions itself at the forefront of precision medicine in neuro-oncology, offering innovative solutions to accelerate drug development and improve patient outcomes in brain cancer treatment.